Publications by authors named "W Jeff Petty"
Background: CALGB 30610 trial demonstrated that once daily thoracic radiotherapy (TRT) was not superior compared to standard twice daily TRT, in patients with limited stage small cell lung cancer. Quality of life outcomes may help oncologists decide the best treatment approach.
Methods: A total of 417 patients on CALGB 30610 participated in the quality-of-life substudy (CALGB 70702), which included the FACT Trial Outcome Index-Lung Cancer (FACT-L TOI), FACT-Esophageal Cancer (FACT-E) Eating and Swallowing Indices, ECOG Acute Esophagitis Scale, Hospital Anxiety and Depression Scale (HADS), difficulty swallowing, EQ-5D, and treatment convenience assessment at baseline, 3, 5, 7, 12, 26, and 52 weeks after starting TRT.
Article Synopsis
- The study aimed to assess if adding the PARP inhibitor talazoparib to the immune checkpoint inhibitor atezolizumab could enhance outcomes for patients with SLFN11-positive extensive stage small cell lung cancer (ES-SCLC) after initial treatment.
- A total of 106 patients were randomized into two groups, showing that the combination therapy (talazoparib plus atezolizumab) led to improved progression-free survival compared to atezolizumab alone, though overall survival rates remained similar between the two groups.
- While the combination therapy improved progression-free survival, it also resulted in higher rates of severe hematological side effects, such as grade 3 anemia, highlighting the need for careful patient selection based on genetic markers
Article Synopsis
- A new lung cancer survivorship clinic workflow was created to specifically address the needs of early-stage lung cancer survivors (LCS) using electronic patient-reported outcomes (ePROs) to collect data on their experiences and care.
- From January 2020 to March 2023, 315 early-stage LCS completed orientation visits, showing high satisfaction rates, although ePRO completion varied significantly by gender and demographics.
- The study found LCS reported lower symptom burdens compared to the general population, but a significant number had moderate to severe symptoms, indicating a need for better outreach and supportive care referrals, particularly for female patients.
Purpose/objectives: Biomarkers for extracranial oligometastatic disease remain elusive and few studies have attempted to correlate genomic data to the presence of true oligometastatic disease.
Methods: Patients with non-small cell lung cancer (NSCLC) and brain metastases were identified in our departmental database. Electronic medical records were used to identify patients for whom liquid biopsy-based comprehensive genomic profiling (Guardant Health) was available.
Neurological adverse events (NAEs) are infrequent immune checkpoint inhibitor (ICI) outcomes poorly characterized in extant research, complicating their clinical management. This study characterized the frequency, severity, patterning and timing of NAEs using a large retrospective registry, including all patients who received at least one dose of an ICI from 2/1/2011-4/7/2022 within our health network. Among 3137 patients, there were 54 NAEs (1.
View Article and Find Full Text PDF